ERBB2 and neoplasm: Overall, while STAT3 inhibition did not significantly impact cell viability, proliferation, or CD44 induction after HER2 inhibition, JAK1 inhibition appeared to sensitize cells to HER2 inhibition and impair proliferation during the recovery phase in CD24+/CD44+ tumor cells (Figure 7).